These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20040702)

  • 41. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
    Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dolutegravir for the treatment of adult patients with HIV-1 infection.
    Wu G; Abraham T; Saad N
    Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):419-26. PubMed ID: 18662108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
    Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
    BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
    Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
    Podany AT; Scarsi KK; Pham MM; Fletcher CV
    Clin Pharmacokinet; 2020 Sep; 59(9):1085-1107. PubMed ID: 32462541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.
    Serrao E; Odde S; Ramkumar K; Neamati N
    Retrovirology; 2009 Mar; 6():25. PubMed ID: 19265512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV integrase inhibitors: a new era in the treatment of HIV.
    Blanco JL; Whitlock G; Milinkovic A; Moyle G
    Expert Opin Pharmacother; 2015 Jun; 16(9):1313-24. PubMed ID: 26001181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].
    Moreno S; Berenguer J
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Greig SL; Deeks ED
    Drugs; 2016 Jun; 76(9):957-68. PubMed ID: 27189707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
    Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
    Evering TH; Markowitz M
    Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
    Ramanathan S; Mathias AA; German P; Kearney BP
    Clin Pharmacokinet; 2011 Apr; 50(4):229-44. PubMed ID: 21348537
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.
    Temesgen Z
    Drugs Today (Barc); 2012 Dec; 48(12):765-71. PubMed ID: 23243633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.